Clinical Trials
45 trialsTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
National Cancer Institute (NCI)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
MK-6482-015
Merck Sharp & Dohme LLC
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Columbia University
LAMPARA
Columbia University
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
NETTER-P
Advanced Accelerator Applications
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
National Cancer Institute (NCI)
BELIEVE-VHL
AC Camargo Cancer Center
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma
Sun Yat-sen University
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
SNIPP
University Health Network, Toronto
LUFOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Mayo Clinic
The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment
Peking Union Medical College Hospital
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
Peking Union Medical College Hospital
MPPGL
Peking Union Medical College Hospital
PUTNET
Excel Diagnostics and Nuclear Oncology Center
EASOAIPPGL
Nanjing First Hospital, Nanjing Medical University
the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma
National Cancer Institute, Egypt
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
National Institutes of Health Clinical Center (CC)
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
Dovitinib in Neuroendocrine Tumors
Abramson Cancer Center at Penn Medicine
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
National Cancer Institute (NCI)
131MIBG to Treat Malignant Pheochromocytoma
National Institutes of Health Clinical Center (CC)
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
National Institutes of Health Clinical Center (CC)
PheoCarcRAD001
Seoul National University Hospital
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center